Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
Portfolio Pulse from Vandana Singh
Cognition Therapeutics (NASDAQ:CGTX) reported mixed results from its Phase 2 'SHINE' study for Alzheimer's treatment CT1812. While there were trends of cognitive improvement and functional benefits, the drug did not achieve statistical significance on secondary efficacy endpoints. The stock fell 35.10% to $1.54 following the news.
July 29, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cognition Therapeutics' stock dropped 35.10% after mixed results from its Phase 2 'SHINE' study for Alzheimer's treatment CT1812. The study showed cognitive improvement trends but failed to achieve statistical significance on secondary endpoints.
The stock price of CGTX fell significantly due to the mixed results of the Phase 2 study. Although there were positive trends in cognitive improvement, the failure to achieve statistical significance on secondary endpoints likely led to investor disappointment.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100